These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 10202049

  • 1. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA, DeBenedette MA, Watts TH, Berinstein NL.
    J Immunol; 1999 Apr 15; 162(8):5003-10. PubMed ID: 10202049
    [Abstract] [Full Text] [Related]

  • 2. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.
    Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH.
    Cell Immunol; 2001 May 25; 210(1):56-65. PubMed ID: 11485353
    [Abstract] [Full Text] [Related]

  • 3. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
    Cayeux S, Richter G, Becker C, Beck C, Aicher A, Pezzutto A, Dörken B, Blankenstein T.
    Eur J Immunol; 1997 Jul 25; 27(7):1657-62. PubMed ID: 9247574
    [Abstract] [Full Text] [Related]

  • 4. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
    Martin-Fontecha A, Cavallo F, Bellone M, Heltai S, Iezzi G, Tornaghi P, Nabavi N, Forni G, Dellabona P, Casorati G.
    Eur J Immunol; 1996 Aug 25; 26(8):1851-9. PubMed ID: 8765031
    [Abstract] [Full Text] [Related]

  • 5. Role of IL-12 and 4-1BB ligand in cytokine production by CD28+ and CD28- T cells.
    Chu NR, DeBenedette MA, Stiernholm BJ, Barber BH, Watts TH.
    J Immunol; 1997 Apr 01; 158(7):3081-9. PubMed ID: 9120260
    [Abstract] [Full Text] [Related]

  • 6. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
    Moro M, Gasparri AM, Pagano S, Bellone M, Tornaghi P, Veglia F, Corti A, Casorati G, Dellabona P.
    Cancer Res; 1999 Jun 01; 59(11):2650-6. PubMed ID: 10363988
    [Abstract] [Full Text] [Related]

  • 7. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus.
    DeBenedette MA, Wen T, Bachmann MF, Ohashi PS, Barber BH, Stocking KL, Peschon JJ, Watts TH.
    J Immunol; 1999 Nov 01; 163(9):4833-41. PubMed ID: 10528184
    [Abstract] [Full Text] [Related]

  • 8. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y, McGowan P, Hellström I, Hellström KE, Chen L.
    J Immunol; 1994 Jul 01; 153(1):421-8. PubMed ID: 7515929
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic antitumor response to cervical cancer in mice immunized with U14 vaccines transfected with costimulatory B7 gene.
    Tao G, Hu J, Zou H, Lin Q, Liu F, Wu Y, Sun Q.
    Chin Med J (Engl); 2001 Jun 01; 114(6):623-7. PubMed ID: 11780440
    [Abstract] [Full Text] [Related]

  • 10. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.
    Lu ZY, Condomines M, Tarte K, Nadal L, Delteil MC, Rossi JF, Ferrand C, Klein B.
    Exp Hematol; 2007 Mar 01; 35(3):443-53. PubMed ID: 17309825
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses.
    Tan JT, Whitmire JK, Ahmed R, Pearson TC, Larsen CP.
    J Immunol; 1999 Nov 01; 163(9):4859-68. PubMed ID: 10528187
    [Abstract] [Full Text] [Related]

  • 13. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y, Hiraoka S, Tomura M, Zhou XY, Yashiro-Ohtani Y, Mori Y, Shimizu J, Ono S, Dunussi-Joannopoulos K, Wolf S, Fujiwara H.
    Int Immunol; 2005 Jan 01; 17(1):73-83. PubMed ID: 15569772
    [Abstract] [Full Text] [Related]

  • 14. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
    Liu R, Jiang W, Yang M, Guo H, Zhang Y, Wang J, Zhu H, Shi R, Fan D, Yang C, Zhu Z, Xie Y, Xiong D.
    J Immunother; 2010 Jun 01; 33(5):500-9. PubMed ID: 20463597
    [Abstract] [Full Text] [Related]

  • 15. Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells.
    Plumas J, Chaperot L, Jacob MC, Molens JP, Giroux C, Sotto JJ, Bensa JC.
    Eur J Immunol; 1995 Dec 01; 25(12):3332-41. PubMed ID: 8566020
    [Abstract] [Full Text] [Related]

  • 16. Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect.
    Liu X, Zhang L, Zhang M, Ma Y, Xu X, Cai Y.
    Chin Med J (Engl); 2000 Feb 01; 113(2):167-71. PubMed ID: 11775545
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J, Chen Y, Moyana T.
    Cancer Gene Ther; 2000 Jul 01; 7(7):1023-33. PubMed ID: 10917205
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.